Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

BACKGROUND: Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatment, with antiretroviral drugs (ARVs) being delivered to nearly 190,000 patients. The analysis of ARV price evolution and market dynamics in Brazil can help anticipate issues soon to affli...

Full description

Bibliographic Details
Main Authors: Constance Meiners, Luis Sagaon-Teyssier, Lia Hasenclever, Jean-Paul Moatti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3156239?pdf=render

Similar Items

Similar Items